Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | BLM | P54132 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 5/20 | 0.42 |
| ▸ | THPO | P40225 | 2/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | EIF4E | P06730 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | TOP1 | P11387 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | UMPS | P11172 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ribose (Furanose) SCHEMBL1040051 | 1.00 | KDM4E (0.50) | KDM4ETP53TDP1MAPTSMN1; SMN2 | |
| Ribose (Furanose) SCHEMBL1193414 | 0.87 | KDM4E (0.48) | KDM4ETP53TDP1MAPTSMN1; SMN2 | |
| Ribose (Furanose) SCHEMBL28792915 | 0.86 | SMN1; SMN2 (0.50) | KDM4ETP53TDP1MAPTSMN1; SMN2 | |
| SCHEMBL15552693 | 0.83 | FBP1 (0.55) | SMN1; SMN2ADORA1UMPS | |
| SCHEMBL4585028 | 0.83 | FBP1 (0.55) | SMN1; SMN2ADORA1UMPS | |
| SCHEMBL6830418 | 0.82 | KDM4E (0.42) | KDM4ETP53TDP1MAPTSMN1; SMN2 | |
| Ribose (Furanose) SCHEMBL218015 | 0.81 | GDA (0.59) | KDM4ETP53TDP1MAPTSMN1; SMN2 | |
| Ribose (Furanose) SCHEMBL14357961 | 0.81 | LMNA (0.39) | KDM4ETP53TDP1MAPTSMN1; SMN2 | |
| SCHEMBL7253811 | 0.79 | CA1 (0.50) | GAA | |
| SCHEMBL3810831 | 0.79 | CA1 (0.50) | GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1011 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12582626-B2 | Methods and compositions for treating cancer | The Wister Institute of Anatomy and Biology (US) | 2026-03-24 | — | — | US | claimed |
| EP-4582090-A2 | COMPOSITION COMPRISING PEGYLATED ARGININE DEIMINASE | Polaris Group (TW) | 2025-07-09 | — | — | EP | claimed |
| EP-3782653-B1 | COMPOSITION COMPRISING PEGYLATED ARGININE DEIMINASE | POLARIS GROUP (TW) | 2025-03-19 | — | — | EP | claimed |
| US-20240415786-A1 | COMPOSITIONS AND METHODS USING AN AUTOPHAGY INDUCER TO ENHANCE INTERMITTENT FASTING | NESTLE SA (CH) | 2024-12-19 | — | — | US | claimed |
| WO-2024224296-A2 | TARGETED PHARMACEUTICAL COMPOSITIONS TO TREAT NEUROLOGICAL CONDITIONS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2024-10-31 | — | — | WO | claimed |
| EP-4422423-A1 | COMPOSITIONS AND METHODS USING AN AUTOPHAGY INDUCER TO ENHANCE INTERMITTENT FASTING | Société des Produits Nestlé S.A. (CH) | 2024-09-04 | — | — | EP | claimed |
| US-20240075050-A1 | Methods and Compositions for Treating Leucine Rich Repeat Kinase 2 (LRRK2)-Associated Disorder or Condition | UNIVERSITY OF CONNECTICUT (US) | 2024-03-07 | — | — | US | claimed |
| US-20240041767-A1 | Mitochondria-Enriched Extracellular Vesicles | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2024-02-08 | — | — | US | claimed |
| WO-2023073054-A1 | COMPOSITIONS AND METHODS USING AN AUTOPHAGY INDUCER TO ENHANCE INTERMITTENT FASTING | Société des Produits Nestlé S.A. (CH) | 2023-05-04 | — | — | WO | claimed |
| US-20220313643-A1 | Methods and Compositions for Treating Cancer | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY | 2022-10-06 | — | — | US | claimed |
| WO-2006074416-A1 | 5-AMINO-4-IMIDAZOLECARBOXAMIDE RIBOSIDE AND ITS NUCLEOBASE AS POTENTIATORS OF ANTIFOLATE TRANSPORT AND METABOLISM | HEALTH RESEARCH INC. (US) | 2006-07-13 | — | — | WO | claimed |
| WO-2005023202-A2 | TUMOR SUPPRESSOR LKB1 KINASE DIRECTLY ACTIVATES AMP-ACTIVATED KINASE | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2005-03-17 | — | — | WO | claimed |
| US-20050002943-A1 | Amp-kinase agonists or adenosine pro-drugs as immuno-stimulating agents | UNIVERSITE LIBRE DE BRUXELLES (BE) | 2005-01-06 | — | — | US | claimed |
| EP-1492564-A2 | AMP-KINASE AGONISTS OR ADENOSINE PRO-DRUGS AS IMMUNO-STIMULATING AGENTS | Université Libre de Bruxelles (BE) | 2005-01-05 | — | — | EP | claimed |
| US-20030212013-A1 | Use of amp kinase activators for treatment type 2 diabetes and insulin resistance | BRIGHAM YOUNG UNIVERSITY | 2003-11-13 | — | — | US | claimed |
| WO-2003037371-A2 | AMP-KINASE AGONISTS OR ADENOSINE PRO-DRUGS AS IMMUNO-STIMULATING AGENTS | UNIVERSITE LIBRE DE BRUXELLES (BE) | 2003-05-08 | — | — | WO | claimed |
| WO-2001097816-A1 | USE OF AMP KINASE ACTIVATORS FOR TREATMENT OF TYPE 2 DIABETES AND INSULIN RESISTANCE | BRIGHAM YOUNG UNIVERSITY (US) | 2001-12-27 | — | — | WO | claimed |
| US-RE34387-E | Method for restoring depleted purine nucleotide pools | DUKE UNIVERSITY (US) | 1993-09-21 | — | — | US | claimed |
| US-5082829-A | 5-amino-4-imidazolecarboxamide riboside to increase adenosine concentration, cardiovascular, seizures | GENSIA PHARMACEUTICALS (US) | 1992-01-21 | — | — | US | claimed |
| US-4575498-A | 5-AMINO-4-IMIDAZOLE CARBOXAMIDE RIBOSIDE | DUKE UNIVERSITY (US) | 1986-03-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12582626-B2 | Methods and compositions for treating cancer | ICOS, PPARD, CD69 | KDM4E 1151/4885TP53 63/4885TDP1 4188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.